Eyenuk, Inc.

Company profile

About Eyenuk, Inc.

Eyenuk, Inc. is a medical AI company that has developed EyeArt, the first and only FDA 510(k)-cleared autonomous artificial intelligence system for detecting vision-threatening diabetic retinopathy (vtDR) and more than mild diabetic retinopathy (mtmDR). The company's mission centers on preventing blindness through early detection, as retinal screening can prevent 95% of vision loss caused by diabetic retinopathy. Eyenuk's platform provides a comprehensive solution spanning screening, triage, and monitoring of retinal diseases. The EyeArt system delivers diagnostic results in under 10 seconds without requiring patient dilation or immediate specialist oversight, making it ideal for deployment in primary care, endocrinology, optometry, and ophthalmology settings. The platform achieves 96% sensitivity and 88% specificity for identifying mtmDR, and 97% sensitivity and 90% specificity for identifying vtDR. Beyond diabetic retinopathy, Eyenuk has expanded its capabilities to detect age-related macular degeneration (AMD) and glaucomatous optic nerve damage, with Class IIb CE mark clearance in the EU. The system integrates seamlessly with existing EHR systems and is compatible with multiple retinal camera models from major manufacturers. Eyenuk serves health systems, primary care clinics, specialty practices, and screening programs globally, helping providers close care gaps, generate revenue through CPT 92229 billing, improve quality metrics like HEDIS and CMS Star Ratings, and enhance Risk Adjustment Factor (RAF) scores through accurate disease documentation.

Company description · Eyenuk, Inc. official website